NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSHealthcare · Biotechnology
-3.37%$20.06
AH$20.00-0.30%vs close
Mkt Cap$2.4B
Float86.23M
O/S119.54M
Vol
$ Vol
RVOL
Inst Own101.9%
SI16.4%
Earnings
Dilution
Financials Summary
Revenue$22.5M
Net Income-$203.82M
Total Assets$769.28M
Free Cash Flow-$148.03M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$202K
Total Equity$683.43M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in NAMS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$769.28M
Liabilities$85.85M
Accounts Receivable$23.15M
Accounts Payable$8.97M
Inventory$0
PP&E (Net)$568K
Goodwill$0
Intangible Assets$407K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $22.5M | $45.56M | $14.09M | $102.69M | $0 | $0 |
| YoY Growth | -50.6% | 223.4% | -86.3% | - | - | - |
| Cost of Revenue | $59K | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $22.44M | $45.56M | $14.09M | $102.69M | $0 | $0 |
| Gross Margin | 99.7% | 100.0% | 100.0% | 100.0% | - | - |
| Research and Development | $141.83M | $151.41M | $159.42M | $86.74M | $28.97M | $4.94M |
| Selling, General, and Administrative | $106.3M | $70.45M | $37.63M | $19.51M | $5.68M | $1.69M |
| Other | $0 | $0 | $0 | $0 | $326K | $0 |
| Total Operating Expenses | $248.13M | $221.85M | $197.06M | $106.25M | $34.98M | $6.63M |
| Operating Income (EBIT) | -$225.68M | -$176.29M | -$182.97M | -$3.56M | -$34.98M | -$6.63M |
| Operating Margin | -1002.9% | -386.9% | -1298.6% | -3.5% | - | - |
| Interest Expense | $0 | $0 | $6.8M | $287K | $411K | $0 |
| Interest Income | $27.59M | $16.88M | $10.22M | $0 | $0 | $851 |
| Other Income (Expense) | $21.86M | -$65.31M | $6.06M | -$19.08M | -$6.81M | -$391K |
| Income Before Tax (EBT) | -$203.82M | -$241.6M | -$176.91M | -$22.63M | -$41.78M | -$7.02M |
| Income Tax Expense | $0 | -$1K | $27K | $0 | $0 | $0 |
| Net Income | -$203.82M | -$241.6M | -$176.94M | -$22.63M | -$41.78M | -$7.02M |
| Net Income Margin | -905.7% | -530.3% | -1255.8% | -22.0% | - | - |
| Supplementary Data | ||||||
| EPS | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | 0.00 |
| Diluted EPS | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | 0.00 |
| Weighted Average OS | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M | 17.75M |
| EBITDA | -$242.32M | -$241.49M | -$176.86M | -$22.34M | -$41.37M | -$6.63M |
| EBITDA Margin | -1076.9% | -530.0% | -1255.2% | -21.8% | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $490M | $771.74M | $340.45M | $467.73M | $60.38M | $1.37M |
| Short-Term Investments | $146.24M | $62.45M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $636.24M | $834.19M | $340.45M | $467.73M | $60.38M | $1.37M |
| Accounts Receivable | $23.15M | $21.3M | $1.88M | $0 | $5.51M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $1.32M | $0 | $0 | $2.07M | -$628K | $0 |
| Total Current Assets | $675.7M | $863.41M | $346.79M | $477.98M | $66.96M | $1.87M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $568K | $673K | $101K | $154K | $216K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $407K | $534K | $170K | $208K | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $138.02M | $138M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $92.61M | $0 | $35K | $156K | -$137.2M | $0 |
| Total Long-Term Assets | $93.58M | $1.21M | $306K | $518K | $1.03M | $138M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $769.28M | $864.62M | $347.1M | $478.5M | $67.99M | $139.87M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $8.97M | $4.74M | $16.92M | $11.85M | $7.07M | $162K |
| Short-Term Debt | $136K | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $3.99M | $6.01M | $8.94M | $0 | $0 | $0 |
| Other Current Liabilities | $72.69M | $91.03M | $15.96M | $18.02M | $0 | $74K |
| Total Current Liabilities | $85.79M | $106.92M | $49.9M | $36.06M | $11.24M | $237K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $66K | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $1.02M | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $7.79M | $12.31M | $0 | $12.17M |
| Total Long-Term Liabilities | $66K | $202K | $8.81M | $12.37M | $126K | $12.17M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $85.85M | $107.12M | $58.7M | $48.43M | $11.36M | $12.41M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $14.28M | $13.44M | $10.17M | $10.05M | $129K | $122.46M |
| Retained Earnings | -$762.39M | -$558.57M | -$316.97M | -$140.04M | -$39.44M | $41K |
| Comprehensive Income & Other | $4.79M | $4.47M | $4.42M | $4.42M | $672K | $0 |
| Other Stockholders' Equity | $1.43B | $1.3B | $595.19M | $560.05M | $95.93M | $4.96M |
| Total Equity | $683.43M | $757.5M | $288.39M | $430.07M | $56.63M | $127.46M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $769.28M | $864.62M | $347.1M | $478.5M | $67.99M | $139.87M |
| Supplementary Data | ||||||
| Total Debt | $202K | $448K | $60K | $126K | $187K | $0 |
| Net Debt | -$489.8M | -$771.29M | -$340.39M | -$467.6M | -$60.19M | -$1.37M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$203.82M | -$241.6M | -$176.94M | -$22.63M | -$41.78M | -$7.07M |
| Depreciation & Amortization | $220K | $113K | $49K | $9K | $5K | $1K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $59.42M | $33.62M | $24.57M | $4.12M | $1.24M | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$13.28M | $0 | $4.03M | -$4.18M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $4.91M | -$12.95M | $5.07M | $4.81M | $6.56M | $0 |
| Other Working Capital | $427K | -$19.73M | -$3.23M | $9.75M | -$2.09M | -$649K |
| Total Working Capital Change | -$7.94M | -$32.67M | $5.87M | $10.37M | $4.47M | -$649K |
| Other Non-Cash Items | $4.33M | $81.98M | $5.23M | $18.8M | $6.55M | $376K |
| Net Cash from Operating | -$147.78M | -$158.56M | -$141.22M | $10.66M | -$29.51M | -$7.34M |
| Investing Activities | ||||||
| Capital Expenditures | -$246K | -$672K | -$24K | -$221K | -$24K | -$16K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$296.73M | -$62.18M | $0 | $0 | $0 | $0 |
| Sales of Investments | $122.06M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$174.92M | -$62.85M | -$24K | -$221K | -$24K | -$16K |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | -$747K | - | -$13.92M |
| Common Stock Issuance | $29.52M | $645.51M | $8.91M | $396.95M | $84.7M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $14M | $0 | -$5.79M | $0 | $0 |
| Net Cash from Financing | $29.52M | $659.51M | $8.91M | $391.9M | $84.7M | $13.92M |
| Forex Effect | $12.76M | -$6.8M | $5.05M | $5.25M | -$4.68M | $30K |
| Net Change in Cash | -$280.42M | $431.29M | -$127.28M | $407.6M | $50.48M | $6.59M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$147.78M | -$158.56M | -$141.22M | $10.66M | -$29.51M | -$7.34M |
| Capital Expenditure | -$246K | -$672K | -$24K | -$221K | -$24K | -$16K |
| Free Cash Flow | -$148.03M | -$159.24M | -$141.24M | $10.44M | -$29.54M | -$7.36M |
| Cash at Beginning | $771.74M | $340.45M | $467.73M | $60.13M | $9.65M | $3.07M |
| Cash at End | $491.32M | $771.74M | $340.45M | $467.73M | $60.13M | $9.67M |